Nigeria is working on COVID-19 vaccine, president says

PUBLISHED: Fri, 07 Jan 2022 07:44:30 GMT
Chijioke Ohuocha
Reuters
Share
Nigeria’s President Muhammadu Buhari speaks during a plenary session at the start of the Paris Peace Forum, in Paris, France, November 11, 2021. REUTERS/Gonzalo Fuentes

ABUJA, Jan 6 (Reuters) – Nigeria is working to develop a COVID-19 vaccine, President Muhammadu Buhari said in a televised interview on Thursday, as the country battles growing cases of the virus.

Health experts say Nigeria needs to triple its vaccination drive from just over 100,000 doses a day to meet its target of inoculating more than half its population by the end of next year.

The West African country has been exploring options to acquire or purchase vaccines through the COVAX facility to enable it to inoculate at least 70% of its population.

It received vaccine donations some of which had a shelf life that left only weeks to administer the shots. Nigeria destroyed more than one million expired vaccines last month.

Read more: Nigeria says found Omicron variant from October samples

“We are working very hard with the ministry of health to develop vaccines,” Buhari said on state television. “We shouldn’t make noise about it until we succeed.”

Nigeria, which has not tested widely for COVID-19, has recorded 245,404 COVID-19 cases and 3,058 deaths since the pandemic started.

In 2017, Nigeria’s cabinet approved a plan to produce basic vaccines with pharmaceutical firm May & Baker Nigeria via a joint venture. Its not clear whether the project took off.

Buhari said his administration is encouraging Nigerians to get inoculated. Fewer than 4% of adults in Africa’s most populous nation of over 200 million have been fully vaccinated.

(Reporting by Chijioke Ohuocha Editing by Alistair Bell)

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.